OT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human eye transplant.

Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point and beat the dexamethasone implant on visual and anatomic measures at 24 weeks.

Kenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.

At AAO 2026, Anjum F. Koreishi, MD, shared how to prevent complications after cataract surgery in patients with uveitis.

Two phase 1 OSPREY cohorts of intravitreal STK-002 for ADOA are dosed; first safety and efficacy data are expected by mid-2027.

David F. Chang, MD, shares how to set realistic refractive IOL expectations and streamline patient counseling.

Timothy Janetos, MD, explained when to refer uveitis to a specialist and why access to uveitis care remains limited.

Himani Goyal, MD, John J. Chen, MD, PhD, and Mark P. Breazzano, MD, FACS, point to academic compensation, optic nerve damage, and who chooses retina.